Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NKTX
NKTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NKTX News
Nkarta Reaches FDA Agreement to Optimize Clinical Trials
3d ago
seekingalpha
Nkarta Reaches Agreement with FDA to Optimize Clinical Trials for NKX019
4d ago
Newsfilter
Nkarta Files $350M Mixed-Securities Offering to Fund Growth
Mar 26 2026
seekingalpha
Nkarta Q4 Earnings Miss Expectations
Mar 25 2026
seekingalpha
NKARTA REPORTS Q4 NET LOSS OF USD 27.408 MILLION
Mar 25 2026
moomoo
NKARTA Reports Q4 Basic EPS of USD -0.37
Mar 25 2026
moomoo
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
Jan 21 2026
Yahoo Finance
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
Dec 02 2025
Globenewswire
Nkarta to Attend Investor Conferences in November
Oct 30 2025
Newsfilter
Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting
Oct 22 2025
Newsfilter
Nkarta Posts Narrower Loss in Q2
Aug 13 2025
NASDAQ.COM
Needham Reiterates Buy on Nkarta, Maintains $10 Price Target
Aug 13 2025
Benzinga
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
Jun 06 2025
Newsfilter
Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed
Jun 06 2025
NASDAQ.COM
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
May 15 2025
Benzinga
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
May 15 2025
Benzinga
Show More News
